Lipid-lowering drugs
Factors Related to Adherence with Treatment of Dyslipidemic Patients on Continuous Use of Oral Lipid Lowering Drugs
... them drugs that require special care by health professionals, both in clinic and in the dispensation of drugs and care offered to patients who use ...and lipid-lowering drugs that make ...
7
Patient factors influencing the prescribing of lipid lowering drugs for primary prevention of cardiovascular disease in UK general practice: a national retrospective cohort study.
... ing lipid lowering drugs extends to secondary prevention and to antihypertensive ...that lipid lowering drugs are effective in women), this can be addressed through better ...
10
Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: single or in combination study in rats
... the lipid-lowering effects of statins ...of lipid-profile, which strongly suggest that PCSK9 inhibitors should be combined with the cur- rently prescribed lipid-lowering drugs to ...
6
Priscription Pattern of Lipid Lowering Drugs among Diabetic and Hypertensive Patients in Five selected Public Health Facilities in Delta State
... of lipid lowering drugs among diabetic and hypertensive patients in five selected Government Health Facilities in Delta ...of lipid profile and routine prescription of lipid ...
8
ANALYSIS OF THE CURRENT STATE AND THE DYNAMICS OF LIPID LOWERING DRUGS IN THE PHARMACEUTICAL MARKET OF UKRAINE
... Ukraine is a part of the international community of countries that have set a goal to decrease mortality from CVDs by 25% in 2025. In this direction, in our opinion, the importance of educational work is unconditional, ...
5
High-fat meal effect on LDL, HDL, and VLDL particle size and number in the Genetics of Lipid-Lowering drugs and diet network (GOLDN): an interventional study
... The present study focused on the PPL response to an acute (1-time) high-fat meal using data derived from the Genetics of Lipid-Lowering Drugs and Diet Network (GOLDN) Study. We sought to describe ...
11
No changes of cholesterol levels with a commercially available glucosamine product in patients treated with lipid lowering drugs: a controlled, randomised, open cross-over trial
... The main finding in our study was that we could not demonstrate any significant effect on total s-cholesterol, s-LDL, S-HDL or s-triglycerides after treatment with the glucosamine product Artrox W on patients treated ...
5
Potential contribution of lifestyle and socioeconomic factors to healthy user bias in antihypertensives and lipid-lowering drugs
... 1. Bairey Merz CN, Alberts MJ, Balady GJ, et al. ACCF/AHA/ ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology ...
9
Factors explaining the gender disparity in lipid-lowering treatment goal attainment rate in Chinese patients with statin therapy
... and/or lipid diabetes medication use), peripheral angiopathy diseases (PAD, including ca- rotid artery plaque, abdominal aortic aneurysm or inter- mittent claudication); (3) cardiovascular risk factors including ...
8
A Cross-Sectional Study to Evaluate Age and Gender Related Differences in Drug Utilization in Ischemic Heart Disease at A Tertiary Care Hospital
... of drugs in patients for Ischemic heart disease (IHD) ...Anti-platelet drugs (100%) followed by Lipid lowering drugs (96%) were most commonly ...of drugs per prescription was ...
8
Endothelial lipase genetic polymorphisms and the lipid-lowering response in patients with coronary artery disease on rosuvastatin
... All patients entering this study were treated with 10mg rosuvastatin daily for four to eight weeks. None of the pa- tients underwent statin treatment for at least one month before entry into this study or took any other ...
6
Effect of lipid-lowering and anti-hypertensive drugs on plasma homocysteine levels
... factors, drugs used for the prevention or treatment of cardiovascular disease may modulate plasma homocysteine ...of drugs, lipid-lowering drugs and anti-hypertensive drugs, on ...
10
Intensive versus Guideline Blood Pressure and Lipid Lowering in Patients with Previous Stroke: Main Results from the Pilot ‘Prevention of Decline in Cognition after Stroke Trial’ (PODCAST) Randomised Controlled Trial
... intensive lipid lowering drugs such as atorvastatin (this drug was on patent when the trial ...and lipid lower- ing could simply reflect a false neutral finding (type II error) such that ...
21
High-density lipoproteins: a novel therapeutic target for cardiovascular disease
... disease. Lipid-lowering drugs like statins, niacin, fibrates, and some newer agents, ie, the apolipoprotein A-I mimetics and the cholesteryl ester transfer protein inhibitors, not only increase HDL ...
6
Under prescribing of prevention drugs and primary prevention of stroke and transient ischaemic attack in UK general practice : a retrospective analysis
... prevention drugs, lipid-lowering drugs were the most commonly clinically indi- cated; over half of the people who had a stroke or TIA were eligible for these ...Statin drugs account for ...
18
A Histological Study of Surgically Resected Appendices in Clinically Suspected Appendicitis with Special Reference to Eosinophils and Mast Cells
... is caused by obstructive changes in the coronary circulation & these changes are mainly due to hyperlipidemia. Present study emphasizes the effect of calcium channel blocker drugs on lipid metabolism. ...
5
Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial factorial randomised controlled trial
... pressure-lowering drugs; need for, or contrain dication to, glyceryl trinitrate; coma (Glasgow coma scale score <8); pure sensory stroke; isolated dysphasia; preceding moderate or severe dependency ...
12
Unintended discontinuation of medication following hospitalisation: a retrospective cohort study
... of drugs was observed in a sub-group analysis, with antiplatelet discontinuation associated with hospitalisation, while for NOACs hospi- talisation was not associated with ...
12
Visit-to-visit lipid variability: Clinical significance, effects of lipid-lowering treatment, and (pharmaco) genetics
... In recent years, visit-to-visit variability of serum lipids has been linked to both clinical outcomes and surrogate markers for vascular disease. In this article, we present an overview of the current evidence connecting ...
27
Changes in circulating lipids level over time after acquiring HCV infection: results from ERCHIVES
... There is biological plausibility for our findings. HCV may alter cholesterol homeostasis through several mech- anisms. HCV infection may produce hypolipidemia through its interference with the mevalonate pathway, ...
9